Goodroe Randy, Bonnema D Dirk, Lunsford Shayna, Anderson Phillip, Ryan-Baille Barbara, Uber Walt, Ikonomidis John, Crumbley Arthur J, VanBakel Adrian, Zile Michael R, Pereira Naveen
Division of Cardiology, Department of Medicine, Medical University of South Carolina and Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina 29425, USA.
J Heart Lung Transplant. 2007 Feb;26(2):145-51. doi: 10.1016/j.healun.2006.11.003.
Left ventricular hypertrophy (LVH) is a known predictor of morbidity and mortality in patients with essential hypertension. The prevalence and significance of LVH in heart transplant recipients is unknown.
Transthoracic echocardiograms were performed as part of a routine protocol 1 year after heart transplantation in 141 consecutive patients. Demographic and echocardiographic data were collected using patients' records and center-specific data from the Cardiac Transplant Research Database and analyzed to determine the prevalence and predictors of LVH at 1 year post-transplantation. Patients were divided into three groups based on left ventricular mass (LVM): normal (LVM <150 g); mild-moderate LVH (LVM 150 to 250 g); and severe LVH (LVM >250 g).
LVH was common at 1 year after heart transplantation, present in 83% of heart transplant recipients. Univariate predictors of severe LVH were increased body mass index (p < 0.01), pre-transplant diabetes mellitus (p = 0.02) and pre-transplant hypertension (p = 0.01). By multivariate analysis, pre-transplant hypertension was the only independent predictor of severe LVH (hazard ratio [HR] 2.3, 95% confidence interval [CI] 1.1 to 5.4, p = 0.05). Heart transplant recipients with severe LVH had significantly decreased survival, as compared to patients with normal LVM and mild-moderate LVH (p = 0.03). After multivariate analysis adjusting for age, race, gender, pre-transplant hypertension and diabetes, severe LVH remained a strong, independent predictor of mortality (HR 3.6, 95% CI 1.0 to 12.1, p = 0.04).
LVH is common at 1 year after heart transplantation and is a strong, independent predictor of increased mortality. Hypertension before transplantation is an independent predictor of the presence of severe LVH at 1 year after heart transplantation.
左心室肥厚(LVH)是原发性高血压患者发病和死亡的已知预测指标。心脏移植受者中LVH的患病率及意义尚不清楚。
对141例连续接受心脏移植的患者在术后1年进行经胸超声心动图检查,这是常规检查的一部分。利用患者记录以及心脏移植研究数据库中特定中心的数据收集人口统计学和超声心动图数据,并进行分析以确定移植后1年LVH的患病率及预测因素。根据左心室质量(LVM)将患者分为三组:正常(LVM<150g);轻度至中度LVH(LVM 150至250g);重度LVH(LVM>250g)。
心脏移植术后1年LVH很常见,83%的心脏移植受者存在LVH。重度LVH的单因素预测指标包括体重指数增加(p<0.01)、移植前糖尿病(p = 0.02)和移植前高血压(p = 0.01)。多因素分析显示,移植前高血压是重度LVH的唯一独立预测因素(风险比[HR]2.3,95%置信区间[CI]1.1至5.4,p = 0.05)。与LVM正常和轻度至中度LVH的患者相比,重度LVH的心脏移植受者生存率显著降低(p = 0.03)。在对年龄、种族、性别、移植前高血压和糖尿病进行多因素分析调整后,重度LVH仍然是死亡率的一个强有力的独立预测因素(HR 3.6,95%CI 1.0至12.1,p = 0.04)。
心脏移植术后1年LVH很常见,是死亡率增加的一个强有力的独立预测因素。移植前高血压是心脏移植术后1年出现重度LVH的独立预测因素。